TriPath's Ventana Her-2/neu test:
This article was originally published in Clinica
TriPath Imaging has received US FDA 510(k) market clearance to use a Ventana-branded version of its interactive histology image analysis system with tissues stained for the breast cancer protein marker HER-2/neu. HER-2/neu analysis helps in the prognosis and prediction of therapy outcomes for breast cancer. The Ventana image analysis system (VIAS) was cleared earlier this year for use with other breast cancer tests, oestrogen and progesterone receptor assays (see Clinica No 1158, p 20). In 2004, TriPath, of Burlington, North Carolina, gave Tucson, Arizona-based Ventana exclusive rights to sell and distribute worldwide a Ventana-branded version of its imaging system, optimised for both Ventana and TriPath assays.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.